Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 8FED 1

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 33Prostatic Neoplasms 26Neoplasms 22Colonic Neoplasms 12Lung Neoplasms 10Colonic Polyps 10Breast Neoplasms 10Rare Diseases 8Adenoma 6Pulmonary Disease, Chronic Obstructive 5Heart Failure 5Rectal Neoplasms 4Ovarian Neoplasms 4Pain 3Mental Disorders 3Death 3Adenomatous Polyps 3Uterine Cervical Neoplasms 2Urinary Incontinence 2Smoking Cessation 2Skin Neoplasms 2Sezary Syndrome 2Respiratory Aspiration 2Renal Insufficiency, Chronic 2Polycystic Ovary Syndrome 2Patient Preference 2Patient Compliance 2Obesity 2Neurologic Manifestations 2Neurofibromatosis 2 2

Interventions

Picibanil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × FED × Lymphatic Abnormalities × Clear all
NCT00010452 2015-03-25

Study of Picibanil (OK432) Sclerotherapy in Children With Macrocystic Lymphatic Malformations

FDA Office of Orphan Products Development

Phase 2/3 Completed
150 enrolled

Lymphangioma, Lymphangioma, Cystic, Lymphatic Abnormalities

Data powered by HemOnc (CC BY 4.0) Colophon âš¡